Fosun subsidiary Wanbang licenses Sirona's SGLT2 inhibitor
This article was originally published in Scrip
Executive Summary
Canadian biotech Sirona Biochem and Wanbang Pharma, a subsidiary of Chinese pharma company Fosun, have struck a licensing deal for Sirona's preclinical SGLT2 inhibitor in China.